Mori E, Tabuchi M, Yoshida T, Yamadori A
Neurology Service, Hyogo Brain and Heart Center, Himeji, Japan.
Stroke. 1988 Jul;19(7):802-12. doi: 10.1161/01.str.19.7.802.
Intracarotid urokinase infusion therapy was performed on 22 patients with evolving cerebral infarction due to acute thromboembolic occlusion of the middle cerebral artery. Mean time from onset of symptoms to start of infusion and mean dosage of urokinase were 4.5 hours and 927,000 units, respectively. Immediate recanalization was achieved in 10 patients (45%) after urokinase therapy. In patients with successful recanalization, rapid amelioration of symptoms followed the restoration of blood flow. Thrombolytic recanalization was associated with reduction of neurologic deficits and of computed tomography-demonstrable infarction volume. The reduction of infarction volume and functional outcome correlated highly with the degree of reflow. Hemorrhagic transformation of infarction occurred in four patients and controllable extracranial bleeding in three patients. These results support the safety and efficacy of urokinase therapy for acute thromboembolic occlusion of the middle cerebral artery.
对22例因大脑中动脉急性血栓栓塞性闭塞而处于进展期脑梗死的患者进行了颈内动脉尿激酶输注治疗。从症状发作到开始输注的平均时间以及尿激酶的平均剂量分别为4.5小时和927,000单位。尿激酶治疗后10例患者（45%）实现了即刻再通。在成功再通的患者中，血流恢复后症状迅速改善。溶栓再通与神经功能缺损和计算机断层扫描显示的梗死体积减小有关。梗死体积的减小和功能结果与再灌注程度高度相关。4例患者发生梗死出血转化，3例患者出现可控的颅外出血。这些结果支持尿激酶治疗大脑中动脉急性血栓栓塞性闭塞的安全性和有效性。
